If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

Dyne Therapeutics Inc (DYN)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. They are utilizing their proprietary FORCE platform to overcome the current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases. With their FORCE platform, they have the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using their FORCE platform, they are assembling a broad portfolio of muscle disease therapeutics, including their lead programs in myotonic dystrophy type 1, or DM1, Duchenne muscular dystrophy, or DMD, and facioscapulohumeral dystrophy, or FSHD. In addition, they plan to expand their portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases, including some with larger patient populations. Their programs are currently all in the preclinical stage. They expect to submit investigational new drug, or IND, applications to the U.S. Food and Drug Administration, or FDA, for product candidates in each of their DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022.
Joshua Brumm Gene Kim
Employees Founded
37 2017


Address: 830 Winter Street, Waltham, MA 02451, US

Telephone: (781) 786-8230

Web page:

IPO information

Expected Date 9/17/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $707.8
Revenues (MM) $0
Net Income (Loss) (MM) $-28.2


What do you think will happen with the DYN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10.3
Shares Revised (MM) 12.25
Expected offer amount (MM) $175.1
Realized offer amount(MM) $232.75
JP Morgan/ Jefferies/ Piper Sandler/ Stifel

Sector: Healthcare

Tweets about $DYN

Tweets volume:

RT volume:


Google Trends Stats